Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Ko, Yoon Ho ^a   Roh, Sang Young ^a   Won, Hye Sung ^a   Jeon, Eun Kyoung ^b   Hong, Sook Hee ^b   Lee, Myung Ah ^b   Kang, Jin Hyoung ^b   Hong, Young Seon ^b   Kim, Min Sik ^b   Jung, Chan Kwon ^b  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; TUMOR MARKER; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE MICROARRAY; CELL NUCLEUS; EVALUATION; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CARCINOMA, ADENOID CYSTIC; CELL NUCLEUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KI-67 ANTIGEN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77958569739     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-30     Document Type: Article

References (39)

1. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. RH Spiro AG Huvos EW Strong, Am J Surg 1974 128 4 512 520 10.1016/0002-9610(74)90265-7 4371368
2. Adenoid cystic carcinoma. A clinicopathologic study with flow cytometric analysis. TC Greiner RA Robinson MD Maves, Am J Clin Pathol 1989 92 6 711 720 2556015
3. Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. YH Ko MA Lee YS Hong KS Lee CK Jung YS Kim DI Sun BS Kim MS Kim JH Kang, Jpn J Clin Oncol 2007 37 11 805 11 10.1093/jjco/hym119 18057012
4. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. RL Dodd NJ Slevin, Oral oncology 2006 42 8 759 769 10.1016/j.oraloncology.2006.01.001 16757203
5. IAP proteins: blocking the road to death's door. GS Salvesen CS Duckett, Nat Rev Mol Cell Biol 2002 3 6 401 410 10.1038/nrm830 12042762
6. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. DC Altieri, Molecular cancer therapeutics 2006 5 3 478 482 10.1158/1535-7163.MCT-05-0436 16546961
7. The role of survivin as a new target of diagnosis and treatment in human cancer. T Yamamoto N Tanigawa, Med Electron Microsc 2001 34 4 207 212 10.1007/s007950100017 11956993
8. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. AI Sarela RC Macadam SM Farmery AF Markham PJ Guillou, Gut 2000 46 5 645 650 10.1136/gut.46.5.645 10764707
9. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. PN Span FC Sweep ET Wiegerinck VC Tjan-Heijnen P Manders LV Beex JB de Kok, Clin Chem 2004 50 11 1986 1993 10.1373/clinchem.2004.039149 15364883
10. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. ET Shinohara A Gonzalez PP Massion H Chen M Li AS Freyer SJ Olson JJ Andersen Y Shyr DP Carbone DH Johnson DE Hallahan B Lu, Cancer 2005 103 8 1685 1692 10.1002/cncr.20951 15742356
11. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. P Grabowski T Kuhnel F Muhr-Wilkenshoff B Heine H Stein M Hopfner CT Germer H Scherubl, Br j Cancer 2003 13;88 1 115 119 10.1038/sj.bjc.6600696 (Pubitemid 36241227)
12. High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma. G Marioni G Ottaviano R Marchese-Ragona L Giacomelli A Bertolin D Zanon F Marino A Staffieri, Acta Otolaryngol 2006 126 2 197 203 10.1080/00016480500266685 16428200
13. Nuclear survivin expression predicts poorer prognosis in glioblastoma. K Shirai Y Suzuki K Oka SE Noda H Katoh J Itoh H Itoh S Ishiuchi H Sakurai M Hasegawa T Nakano, J Neurooncol 2009 91 3 353 8 10.1007/s11060-008-9720-4 18953492
14. Survivin: a new target for anti-cancer therapy. BM Ryan N O'Donovan MJ Duffy, Cancer Treat Rev 2009 35 7 553 562 10.1016/j.ctrv.2009.05.003 19559538
15. Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. S Nordgard G Franzen M Boysen TB Halvorsen, Laryngoscope 1997 107 4 531 536 10.1097/00005537-199704000-00019 9111386
16. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. JG Izant H Weintraub, Science 1985 229 4711 345 352 10.1126/science.2990048 2990048
17. Apoptosis is inversely related to bcl-2 but not to bax expression in salivary gland tumours. Y Soini U Tormanen P Paakko, Histopathology 1998 32 1 28 34 10.1046/j.1365-2559.1998.00334.x 9522213
18. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. G Shaulsky N Goldfinger V Rotter, Cancer Res 1991 51 19 5232 5237 1717142
19. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. M Kappler M Kotzsch F Bartel S Fussel C Lautenschlager U Schmidt P Wurl M Bache H Schmidt H Taubert A Meye, Clin Cancer Res 2003 9 3 1098 1104 12631613
20. Survivin, versatile modulation of cell division and apoptosis in cancer. DC Altieri, Oncogene 2003 22 53 8581 8589 10.1038/sj.onc.1207113 14634620
21. Survivin expression in oral squamous cell carcinoma. L Lo Muzio G Pannone S Staibano MD Mignogna C Rubini MA Mariggio M Procaccini F Ferrari G De Rosa DC Altieri, Br j Cancer 2003 89 12 2244 2248 10.1038/sj.bjc.6601402 14676801
22. Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma. SF Preuss A Weinell M Molitor R Semrau M Stenner U Drebber I Wedemeyer TK Hoffmann O Guntinas-Lichius JP Klussmann, Head Neck 2008 30 10 1318 1324 10.1002/hed.20876 18704972
23. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Y Dong L Sui Y Watanabe K Sugimoto M Tokuda, Anticancer Res 2002 22 4 2377 2383 12174930
24. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. K Freier S Pungs C Sticht C Flechtenmacher P Lichter S Joos C Hofele, Int J Cancer 2007 120 4 942 946 10.1002/ijc.22380 17187360
25. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. P Fortugno NR Wall A Giodini DS O'Connor J Plescia KM Padgett S Tognin PC Marchisio DC Altieri, J Cell Sci 2002 115 Pt 3 575 585 11861764
26. Nuclear or cytoplasmic expression of survivin: what is the significance? F Li J Yang N Ramnath MM Javle D Tan, Int J Cancer 2005 114 4 509 512 10.1002/ijc.20768 15578717
27. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Z Khan RP Tiwari R Mulherkar NK Sah GB Prasad BR Shrivastava PS Bisen, Head Neck 2000 31 8 1039 1048 10.1002/hed.21071
28. Survivin multifaceted activity in head and neck carcinoma: current evidence and future therapeutic challenges. G Marioni E D'Alessandro A Bertolin A Staffieri, Acta Otolaryngol 2009 25 1 6 10.1080/00016480902856588
29. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. BM Lippert SK Knauer V Fetz W Mann RH Stauber, Int J Cancer 2007 121 6 1169 1174 10.1002/ijc.22941 17617794
30. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. AG Uren L Wong M Pakusch KJ Fowler FJ Burrows DL Vaux KH Choo, Curr Biol 2000 10 21 1319 1328 10.1016/S0960-9822(00) 00769-7 11084331
31. Survivin expression is associated with features of biologically aggressive prostate carcinoma. SF Shariat Y Lotan H Saboorian SM Khoddami CG Roehrborn KM Slawin R Ashfaq, Cancer 2004 100 4 751 757 10.1002/cncr.20039 14770431
32. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. F Rodel J Hoffmann L Distel M Herrmann T Noisternig T Papadopoulos R Sauer C Rodel, Cancer Res 2005 65 11 4881 4887 10.1158/0008-5472.CAN-04-3028 15930309
33. Survivin promotes cell proliferation in human hepatocellular carcinoma. T Ito K Shiraki K Sugimoto T Yamanaka K Fujikawa M Ito K Takase M Moriyama H Kawano M Hayashida T Nakano A Suzuki, Hepatology 2000 31 5 1080 1085 10.1053/he.2000.6496 10796883
34. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. C Cohen CM Lohmann G Cotsonis D Lawson R Santoianni, Mod Pathol 2003 16 6 574 583 10.1097/01.MP.0000073868.31297.B0 12808063
35. Survivin expression is a prognostic marker in pancreatic cancer patients. K Kami R Doi M Koizumi E Toyoda T Mori D Ito K Fujimoto M Wada S Miyatake M Imamura, Surgery 2004 136 2 443 448 10.1016/j.surg.2004.05.023 15300213
36. Survivin expression is significantly higher in pN+ oral and oropharyngeal primary squamous cell carcinomas than in pN0 carcinomas. G Marioni A Bedogni L Giacomelli SM Ferraro A Bertolin E Facco A Staffieri F Marino, Acta Otolaryngol 2005 125 11 1218 1223 10.1080/00016480510038194 16353406
37. Bcl-2 protects endothelial cells against gamma-radiation via a Raf-MEK-ERK-survivin signaling pathway that is independent of cytochrome c release. P Kumar IK Coltas B Kumar DB Chepeha CR Bradford PJ Polverini, Cancer Res 2007 67 3 1193 1202 10.1158/0008-5472.CAN-06-2265 17283155
38. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. G Carlinfante M Lazzaretti S Ferrari B Bianchi P Crafa, Pathol Res Pract 2005 200 11-12 791 799 10.1016/j.prp.2004.08.008 15792122
39. Adenoid cystic carcinoma: use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. L Norberg-Spaak I Dardick T Ledin, Head Neck 2000 22 5 489 497 10.1002/1097-0347(200008)22:5<489::AID-HED8>3.0.CO;2-X 10897109